GlassScriptPhysician profile
John M Hukriede
NPI 1518252725
$2,751.28
in general payments reported to CMS, 2019-2025
13 companies · $821 in 2025
The $821 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $744 · 2024: $1,186 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.44 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $861.96 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $385.40 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $297.46 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.76 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $210.23 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $176.82 | 2024-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $171.86 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $170.64 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $107.76 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $81.19 | 2023-2025 | Uzedy |
| Inspire Medical Systems, INC. | $25.06 | 2025 | Inspire |
| Braeburn INC. | $21.10 | 2024 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $13.04 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hukriede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.